NovaBay Pharmaceuticals, Inc. (formerly known as NovaCal Pharmaceuticals, Inc.) Spotlights Positive Results for New Class of Anti-Infectives at 50th Annual ICAAC Meeting

EMERYVILLE, Calif., Sept. 16, 2010 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, delivered four poster presentations on its Aganocide compounds at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston, MA.